
GratXray
Bringing 3D phase contrast x-ray imaging to medicine.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
investor investor | €0.0 | round | |
N/A | €0.0 | round | |
€50.0k | Grant | ||
Total Funding | 000k |
EUR | 2018 | 2021 | 2022 | 2023 |
---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 |
EBITDA | 0000 | 0000 | 0000 | 0000 |
Profit | 0000 | 0000 | 0000 | 0000 |
EV | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
GratXray is a pioneering medical technology startup specializing in advanced imaging systems for breast cancer diagnosis. The company leverages phase contrast enhanced X-ray imaging to provide unprecedented tumor visibility, accuracy, and patient comfort. This innovative approach aims to make breast cancer diagnosis more accurate and less painful, ultimately improving patient outcomes.
GratXray serves healthcare providers, including hospitals and diagnostic centers, that require precise and reliable imaging solutions for breast cancer detection. The company operates in the medical technology market, focusing on diagnostic imaging—a critical segment within the broader healthcare industry.
The business model of GratXray involves the development, manufacturing, and marketing of its proprietary imaging systems. The company generates revenue through the sale of these systems to healthcare institutions. Additionally, GratXray may offer maintenance services and software updates, providing ongoing support and ensuring the longevity and effectiveness of their products.
The core team at GratXray is composed of experienced professionals with a strong background in both scientific research and industry practice. This includes co-founders, executives, and board members who have previously led successful medical device companies. Their combined expertise ensures that GratXray remains at the forefront of innovation and quality in medical diagnostics.
As a spin-off from ETH Zurich and the Paul Scherrer Institute (PSI), GratXray benefits from a rich heritage of scientific excellence and cutting-edge research. The company's mission is to use its knowledge and passion to enhance the wellbeing of people, animals, and the environment by offering high-quality, value-added solutions that exceed customer expectations.
GratXray's vision is to become the global leader in accurate and patient-friendly medical diagnostic solutions. By continuously improving their technology and maintaining a strong commitment to quality, GratXray aims to reduce healthcare costs, ease the burden on society, and save lives.
Keywords: Breast Cancer, Diagnosis, Imaging Systems, Phase Contrast X-ray, Medical Technology, Healthcare, Innovation, Patient Comfort, Accurate Detection, ETH Zurich Spin-off.